Literature DB >> 9533659

pANCA represents a cross-reactivity to enteric bacterial antigens.

F Seibold1, S Brandwein, S Simpson, C Terhorst, C O Elson.   

Abstract

pANCA (perinuclear antineutrophil cytoplasmic antibodies) occur at a high frequency in patients with ulcerative colitis. The purpose of this study was to investigate the frequency of pANCA in different mouse models of colitis and to determine whether there is any cross-reactivity of pANCA with bacterial antigens. Sera from 146 colitic mice and controls and from 30 patients with ulcerative colitis were tested for the presence of pANCA by indirect immunofluorescence with or without prior absorption with homogenized murine cecal bacteria. pANCA was found in 24 of 36 IL10(-/-) mice. In contrast to the human pANCA, both nuclear and perinuclear staining was found. Absorption of either human or mouse pANCA-positive sera with enteric bacterial antigens greatly reduced or abolished the specific perinuclear staining of pANCA. We conclude that pANCA occurs not only in humans but also in IL19(-/-) mice with colitis and likely represents a cross-reactivity with enteric bacterial antigens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9533659     DOI: 10.1023/a:1023203118100

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  25 in total

1.  Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity.

Authors:  F Shanahan; R H Duerr; J I Rotter; H Yang; L R Sutherland; C McElree; C J Landers; S R Targan
Journal:  Gastroenterology       Date:  1992-08       Impact factor: 22.682

2.  Spontaneously colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora.

Authors:  S L Brandwein; R P McCabe; Y Cong; K B Waites; B U Ridwan; P A Dean; T Ohkusa; E H Birkenmeier; J P Sundberg; C O Elson
Journal:  J Immunol       Date:  1997-07-01       Impact factor: 5.422

Review 3.  Do stress proteins play a role in arthritis and autoimmunity?

Authors:  J Winfield; W Jarjour
Journal:  Immunol Rev       Date:  1991-06       Impact factor: 12.988

4.  Antigen from colon of germfree rats and antibodies in human ulcerative colitis.

Authors:  P Perlmann; S Hammarström; R Lagercrantz; B E Gustafsson
Journal:  Ann N Y Acad Sci       Date:  1965-06-30       Impact factor: 5.691

5.  Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis.

Authors:  F Seibold; D Slametschka; M Gregor; P Weber
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

6.  Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis.

Authors:  B Nölle; U Specks; J Lüdemann; M S Rohrbach; R A DeRemee; W L Gross
Journal:  Ann Intern Med       Date:  1989-07-01       Impact factor: 25.391

7.  Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene.

Authors:  B Sadlack; H Merz; H Schorle; A Schimpl; A C Feller; I Horak
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

8.  Interleukin-10-deficient mice develop chronic enterocolitis.

Authors:  R Kühn; J Löhler; D Rennick; K Rajewsky; W Müller
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

9.  Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases.

Authors:  A H Mulder; G Horst; E B Haagsma; P C Limburg; J H Kleibeuker; C G Kallenberg
Journal:  Hepatology       Date:  1993-03       Impact factor: 17.425

10.  Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells.

Authors:  F Powrie; M W Leach; S Mauze; S Menon; L B Caddle; R L Coffman
Journal:  Immunity       Date:  1994-10       Impact factor: 31.745

View more
  25 in total

Review 1.  Diagnostic methodologies: serology, endoscopy, and radiology.

Authors:  T Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2001-12

Review 2.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

3.  Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.

Authors:  Marla Cindy Dubinsky
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

4.  Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells.

Authors:  Dan Blat; Ehud Zigmond; Zoya Alteber; Tova Waks; Zelig Eshhar
Journal:  Mol Ther       Date:  2014-03-06       Impact factor: 11.454

Review 5.  Immunogenetic phenotypes in inflammatory bowel disease.

Authors:  Marla-C Dubinsky; Kent Taylor; Stephan-R Targan; Jerome-I Rotter
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

6.  ASCA: genetic marker, predictor of disease, or marker of a response to an environmental antigen?

Authors:  F Seibold
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

Review 7.  Immunopathogenesis of inflammatory bowel disease.

Authors:  David Q Shih; Stephan R Targan
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 8.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

9.  Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response.

Authors:  E Furrie; S Macfarlane; J H Cummings; G T Macfarlane
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

10.  High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis.

Authors:  P R Fleshner; E A Vasiliauskas; L Y Kam; N E Fleshner; J Gaiennie; M T Abreu-Martin; S R Targan
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.